Aptose Biosciences Inc. (NASDAQ:APTO – Get Free Report) (TSE:APS) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 2,090,000 shares, a growth of 1,012.9% from the December 31st total of 187,800 shares. Based on an average trading volume of 6,360,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 3.7% of the shares of the company are sold short.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. 26.62% of the stock is owned by institutional investors.
Aptose Biosciences Price Performance
NASDAQ:APTO opened at $0.19 on Wednesday. The company has a market cap of $11.54 million, a P/E ratio of -0.06 and a beta of 0.87. The firm’s fifty day moving average price is $0.21 and its two-hundred day moving average price is $0.36. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.20.
Analyst Ratings Changes
Check Out Our Latest Report on APTO
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
See Also
- Five stocks we like better than Aptose Biosciences
- Investing in Commodities: What Are They? How to Invest in Them
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- What Does the Future Hold for Eli Lilly?
- What does consumer price index measure?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.